This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Feb 8;383(9916):491-2.

doi: 10.1016/S0140-6736(13)62151-0. Epub 2013 Nov 5.

Interferon-free hepatitis C treatment: one pill to fit all?

Margaret E Hellard¹, Joseph S Doyle²

Affiliations

Affiliations

¹ Centre for Population Health, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia; Department of Epidemiology and Preventative Medicine, Monash University, VIC, Australia. Electronic address: hellard@burnet.edu.au.
² Centre for Population Health, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia; Department of Epidemiology and Preventative Medicine, Monash University, VIC, Australia.

PMID: 24209978
DOI: 10.1016/S0140-6736(13)62151-0

Comment

Interferon-free hepatitis C treatment: one pill to fit all?

Margaret E Hellard et al. Lancet. 2014.

. 2014 Feb 8;383(9916):491-2.

doi: 10.1016/S0140-6736(13)62151-0. Epub 2013 Nov 5.

Authors

Margaret E Hellard¹, Joseph S Doyle²

Affiliations

¹ Centre for Population Health, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia; Department of Epidemiology and Preventative Medicine, Monash University, VIC, Australia. Electronic address: hellard@burnet.edu.au.
² Centre for Population Health, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia; Department of Epidemiology and Preventative Medicine, Monash University, VIC, Australia.

PMID: 24209978
DOI: 10.1016/S0140-6736(13)62151-0

No abstract available

PubMed Disclaimer

Comment on

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Lawitz E, et al. Lancet. 2014 Feb 8;383(9916):515-23. doi: 10.1016/S0140-6736(13)62121-2. Epub 2013 Nov 5. Lancet. 2014. PMID: 24209977 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations